<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/93CE00F1-68A1-47CE-BEB4-02425A802F36"><gtr:id>93CE00F1-68A1-47CE-BEB4-02425A802F36</gtr:id><gtr:name>N4 Pharma UK Limited</gtr:name><gtr:address><gtr:line1>N4 Pharma Ltd, Weston House,1 Bradgate Park View,Chellaston</gtr:line1><gtr:city>Derby</gtr:city><gtr:postCode>DE73 5UJ</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93CE00F1-68A1-47CE-BEB4-02425A802F36" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>93CE00F1-68A1-47CE-BEB4-02425A802F36</gtr:id><gtr:name>N4 Pharma UK Limited</gtr:name><gtr:address><gtr:line1>N4 Pharma Ltd, Weston House,1 Bradgate Park View,Chellaston</gtr:line1><gtr:city>Derby</gtr:city><gtr:postCode>DE73 5UJ</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>118509.0</gtr:offerGrant><gtr:projectCost>169298.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A5EA9B6D-8061-4A77-A8C9-FD00831AE8AF"><gtr:id>A5EA9B6D-8061-4A77-A8C9-FD00831AE8AF</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:surname>Theobald</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=132673"><gtr:id>49F25E1C-A92A-4407-B389-2949B22E1D46</gtr:id><gtr:title>NUVEC a platform technology for the vaccine delivery</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>132673</gtr:grantReference><gtr:abstractText>Nanotechnology platforms, including N4?s propriety NUVEC, are being investigated as vaccine carriers, adjuvants, and drug delivery systems. DNA vaccination indicates great potential for combating a variety of diseases including cancer. Safe and efficient delivery of plasmid DNA to initiate immune responses remains a major barrier in bringing DNA vaccination into human medicine. N4?s NUVEC is a novel platform capable of delivering a range of therapeutic biomolecules whilst simultaneously stimulating the immune system.</gtr:abstractText><gtr:fund><gtr:end>2017-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>118509</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">132673</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>